Product Description: Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 μM) over MAO-A (IC50=580 μM)[1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8?μM) than at resting (IC50=262?μM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].
Applications: Neuroscience-Neuromodulation
Formula: C17H19FN2O2
Citations: Ecotoxicol Environ Saf. 2023 Aug 7;262:115284./Behav Brain Res. 2023 Nov 30:114787.
References: [1]Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50(20), 4909-4916./[2]C Caccia, et al.Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006 Oct 10;67(7 Suppl 2):S18-23./[3]Michele Morari, et al. Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.J Pharmacol Exp Ther. 2018 Feb;364(2):198-206.
CAS Number: 133865-89-1
Molecular Weight: 302.34
Compound Purity: 99.89
Research Area: Neurological Disease
Solubility: DMSO : ≥ 100 mg/mL
Target: Monoamine Oxidase
English
Deutsch
